
Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to high-quality neurological and neurosurgical care in Northern California. The five-story, 129,000-square-foot facility will be located at the corner of César Chávez and Valencia streets (3555 César Chavez Street) in San Francisco and is expected to open in 2028. Designed as a regional destination for brain health, the complex will unite care delivery, advanced diagnostics and research in one location.
'Sutter Health has a bold vision for brain health, and that vision includes building a state-of-the-art advanced neuroscience complex in San Francisco,' said Sutter Health President and CEO Warner Thomas. 'CPMC has cared for this community since the 1850s, and we're proud to continue that legacy by investing in a destination for neurological care that will serve patients and families locally and across the region. Our mission drives us to deliver accessible, high-quality care that fuels innovation and expands access so that more people can benefit from the highest standards of neurological health closer to home.'
'San Francisco is leading the nation in providing cutting-edge health care, and this project will bring exceptional neurological care to the heart of our city and better health outcomes for our residents,' said Mayor Daniel Lurie. 'Thank you to Sutter Health for their commitment to our city, to our residents, and to the Mission District. Together, we're building stronger, healthier communities and strengthening San Francisco's comeback.'
High-Tech Hub for Brain Health
This $442 million investment underscores Sutter Health's long-term commitment to expanding access to specialized, high-acuity care in San Francisco and the broader Bay Area. When complete, the Sutter Advanced Neuroscience Complex at Mission Bernal will bring together approximately 80 physicians and clinicians across range of neurological specialties – including Alzheimer's disease and dementia, ALS, headache, neurosurgery, neurology, epilepsy, neuro-oncology and movement disorders – to deliver seamless, integrated care in one location.
The new complex will house a full spectrum of services, including neurology, neurosurgery, imaging, lab, infusion, rehabilitation and an on-site ambulatory surgery center. Patients will also benefit from direct access to leading research and clinical trials, further supporting advancements in diagnosis and treatment.
Two of Sutter's nationally recognized programs – the Ray Dolby Brain Health Center and the Forbes Norris MDA/ALS Research and Treatment Center – will relocate to the new complex, enabling greater capacity and deeper collaboration among specialists.
The site will also include underground parking to improve convenience for patients and visitors. In a related investment, Sutter plans to add two neurological intervention suites to the adjacent CPMC Mission Bernal campus hospital by 2027. These suites will offer advanced imaging and enable rapid detection and minimally invasive treatment of life-threatening neurological conditions.
'Our goal is to provide coordinated, comprehensive access to integrated care that merges the expertise of neurologists and neurosurgeons,' said Dr. Lewis Leng, a neurosurgeon with Sutter West Bay Medical Group. 'The new Sutter Advanced Neuroscience Complex at Mission Bernal will create more access to care for patients with neurological conditions and provide them the opportunity to take advantage of Sutter's award-winning neuroscience treatment and clinical research.'
Christina Oh, president of Sutter's Greater San Francisco Division, added, 'Patients will be able to come to this location and visit their specialist, receive diagnostic lab and imaging, as well as outpatient procedures all in one complex. Having all these services under one roof will create a more convenient, coordinated experience.'
The Sutter Advanced Neuroscience Complex is part of Sutter Health's broader strategy to invest nearly $1 billion in healthcare infrastructure across San Francisco over the next five years. This initiative aims to significantly expand access to specialized medical care, such as Sutter's new Otolaryngology-Head and Neck Surgery program, and enhance the overall patient experience.
A Vision for Advanced Care and Clinical Training
The Mission Bernal Care Complex is part of a larger effort by Sutter Health to address the growing healthcare needs of Northern California, with more than two dozen new facilities currently in development. Beyond expanding access, this complex reflects Sutter's strong commitment to education and workforce development, with plans to train over 1,000 medical residents and fellows by 2030. Sutter CPMC plays a key role in this effort, currently training residents and fellows in nationally accredited Graduate Medical Education programs across a wide range of specialties, including advanced heart failure and transplant cardiology, cardiovascular disease, internal medicine, gastroenterology, hand surgery, hematology-oncology, ophthalmology, pulmonary and critical care medicine, psychiatry and transplant hepatology. CPMC also offers additional training in neurocritical care, among other areas.
'This groundbreaking represents a pivotal moment in advancing Sutter Health's mission to provide high-quality, compassionate and innovative care,' said Ken McNeely, chair of the Sutter Health Board of Directors. 'It reflects our dedication to meeting the evolving healthcare needs of our community while preparing the next generation of physicians and care teams to carry that mission forward.'
For more information about the Sutter Advanced Neuroscience Complex at Mission Bernal and Sutter Health's ongoing commitment to healthcare excellence, please visit www.sutterhealth.org.
About Sutter Health
Sutter Health is a not-for-profit health care system dedicated to providing comprehensive care throughout California. Committed to community partnerships and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent health care more connected and accessible. Sutter Health currently serves nearly 3.5 million patients, thanks to a dedicated team of more than 57,000 employees and clinicians and 12,000+ affiliated physicians, with a unified focus on expanding care to serve more patients.
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming health care, at Sutter Health, getting better never stops.
Learn more about how Sutter Health is transforming health care at sutterhealth.org and vitals.sutterhealth.org.
Attachments Artist rendering: Sutter Advanced Neuroscience Complex in San Francisco
Groundbreaking for Sutter Advanced Neuroscience Complex in San Francisco
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
4 hours ago
- Business Upturn
Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs
Austin, June 29, 2025 (GLOBE NEWSWIRE) — Cardiovascular Information System Market Size & Growth Analysis: According to SNS Insider, the Cardiovascular Information System Market was valued at USD 1.24 billion in 2023 and is projected to reach USD 2.8 billion by 2032, growing at a CAGR of 9.4% over the forecast period of 2024–2032. The increasing prevalence of cardiovascular diseases and the need for extensive data management in cardiac care are driving the growth of the global cardiovascular information system market. Emerging technologies including cloud-based solutions, artificial intelligence, and EHR interoperability, are filling clinical workflows. Furthermore, increasing digitization of healthcare, in addition to an improved patient outcomes plan, is anticipated to propel widespread adoption of CVIS across hospitals & specialty care centers. Get a Sample Report of Cardiovascular Information System Market@ The U.S. cardiovascular information system market was estimated at USD 0.33 billion in 2023 and is expected to reach USD 0.73 billion by 2032, at a CAGR of 8.64% during the forecast period of 2024-2032 The North American cardiovascular information system market is dominated by the U.S., attributable to high-end healthcare infrastructure combined with high acceptance of electronic health records and huge investments in digital health technologies. The major CVIS vendors based in this country, coupled with the large number of cardiovascular procedures performed, are continuing to drive the U.S. to a commanding lead in the region. Major Players Analysis Listed in this Report are: Philips Healthcare (IntelliSpace Cardiovascular, Xcelera) Siemens Healthineers (syngo Dynamics, GE Healthcare (Centricity Cardio Enterprise, MUSE Cardiology Information System) McKesson Corporation (McKesson Cardiology, Horizon Cardiology) Agfa Healthcare (IMPAX CV, Enterprise Imaging for Cardiology) Fujifilm Medical Systems (Synapse Cardiovascular, Synapse VNA) LUMEDX Corporation (CardioStar, HealthView CVIS) Cerner Corporation (PowerChart Cardiovascular, CVNet) Merge Healthcare (an IBM Company) (Merge Cardio, Merge Hemo) Digisonics Inc. (DigiView, DigiNet Pro) Cardiovascular Information System Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.24 Billion Market Size by 2032 US$ 2.8 Billion CAGR CAGR of 9.4% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis: Based on the System, the CVIS Segment Leads the Market In 2023, the cardiovascular information system (CVIS) segment held the highest market share due to the fact that it supports the management, storage, and analysis of cardiovascular data from multiple modalities. By enabling image archiving, real-time access, and clinical EHR integration, CVIS boosts workflow efficiency in cardiac care. Use has also grown, due to the growing need for centralized data management and interoperability within healthcare settings. Web-Based Segment Dominates the Market by Mode of Operation The web-based segment accounted for the largest share in 2023 with a 73% market share, owing to the ease with which this type of system can be deployed, its scalability, and cost-effectiveness. These are essential systems for timely decision-making in cardiovascular care, and their connectivity helps provide real-time access to patient data from various locations. Because they demand little to no infrastructure and integrate easily with existing hospital networks, healthcare providers are increasingly opting for a web-based system. By End User, the Hospitals Segment dominated the Cardiovascular Information System Market The hospital segment accounted for the highest share of the CVIS market in 2023. Due to the high number of cardiovascular procedures carried out in a hospital setting, as well as the healthcare organizations' demand for integrated data management systems. SCV and other partners' healthcare professionals, complex imaging workflows, imaging data, and patient records that hospitals manage require comprehensive solutions such as CVIS. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Cardiovascular Information System Market Segmentation By Mode Of Operation Web-based Cloud-based On-site By System By End User Hospitals Large Hospitals Medium-sized Hospitals Small Hospitals Diagnostic Centers Regional Trends: North America to Dominate Cardiovascular Information System Market; Asia-Pacific to Witness Fastest Growth The cardiovascular information system (CVIS) market was dominated by North America in 2023, with 37% market share, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of health IT systems in this region. From the perspective of the growth factors, major industry presence, solid government support & initiatives for EHR, and large investment in hospitals' digitization were a few that complemented the market growth. The Asia-Pacific region is anticipated to exhibit the fastest growth over the forecast period in the cardiovascular information system market. Some of the major factors driving the growth of the cardiovascular diagnostics market are rapid urbanization, increasing healthcare spending, and increasing awareness of the importance of good cardiovascular health. Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Adoption Rates of CVIS, 2023 5.2 Device Integration Trends, 2023 5.3 Healthcare Spending on CVIS, by Region, 2023 5.4 Regulatory Compliance and Standardization Trends 5.5 Feature Adoption Trends, 2023 6. Competitive Landscape 7. Cardiovascular Information System Market by Mode Of Operation 8. Cardiovascular Information System Market by System 9. Cardiovascular Information System Market by End User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Buy a Single-User PDF of Cardiovascular Information System Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
9 hours ago
- Business Upturn
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
By GlobeNewswire Published on June 29, 2025, 16:00 IST Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' – making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe – including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio – designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor – please visit here. – ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew [email protected] *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
10 hours ago
- Yahoo
A woman was told she had Alzheimer's 13 years ago. Now she's walking the width of the U.S. after reversing her illness
Judy Benjamin was only 67 when she was diagnosed with Alzheimer's, the devastating disease her mother and several uncles all suffered from. The symptoms started slowly; a forgotten phone number, trouble reading the newspaper. But Benjamin soon found reason to panic after a brain scan showed damage and amyloid plaque build-up — hallmarks of Alzheimer's, the progressive neurodegenerative disorder that typically affects memory, thinking, and behavior. Now 81, Benjamin is in the midst of an epic cross-country walk to prove to herself, and others, that reversal of Alzheimer's symptoms is possible thanks to a specific, science-backed protocol — and she's living proof. Having started her journey April 5 in San Diego, her hopes to make it to Saint Augustine, Florida, by October 5. She's being accompanied by a support team, and a film crew shooting footage for a documentary. This week she celebrated hitting 1,000 miles. 'I've been really thrilled with the people I've met along the way,' Benjamin told The Independent . 'Everyone knows someone with Alzheimer's and they're very interested in my story because I reversed my cognitive decline by radically changing my life.' Getting to this point took a series of small steps and big ones as Benjamin navigated her diagnosis. Her symptoms started shortly after her own mother died of the disease 20 years after her initial diagnosis. "I was working overseas and started to get really worried because I couldn't remember things — even my own phone number or locker combination," she recalled to Fox News Digital. "I got lost driving, when I'm always really good about direction." Scans of Benjamin's brain showed lots of amyloid plaque — proteins that, when built up on the brain, can result in nerve cell death — and damage to the right and left parietal areas of her brain. Located behind the brain's frontal lobe, the parietal lobe helps with location awareness and processes your sense of touch, according to the Cleveland Clinic. "I knew that it was going downhill really quickly, and I was extremely depressed and distressed about that,' she said. In an attempt to chart a new path forward, Benjamin met with Dr. Dale Bredesen at a friend's urging. Bredesen, an internationally recognized expert in the mechanisms of neurodegenerative diseases and the Chief Science Officer of Apollo Health, had been developing a protocol to reverse the signs and symptoms of Alzheimer's but had yet to test it on a patient. He's long been a believer that Alzheimer's isn't just preventable — it's reversible, too. So, Benjamin seeking treatment at the time Bredesen was looking for a 'patient zero' was kismet. Brededsen recalled Benjamin taking 'copious notes' during her first appointment due to her poor memory. He had Benjamin follow his ReCODE (for 'reversal of cognitive decline') protocol, which included changes to Benjamin's diet and exercise routine, as well as making adjustments to her sleep habits and starting meditation. As Bredesen explained to The Independent about ReCODE: 'The bottom line is that it is a personalized, precision medicine protocol that addresses the drivers specific to each person (so it is based on each person's lab results), and these drivers are in three major groups —energetics (blood flow, oxygenation, etc.), inflammation (from any of many different causes), and toxicity (inorganics, organics, and biotoxins) — and three lesser groups — trophic support (hormones, nutrients, and growth factors), neurotransmitters (such as acetylcholine, which is needed for memory), and stress.' Bredesen noted, too, that despite published documentation of the ways in which cognitive decline can be reversed, the vast majority of people remain unaware that it is often possible. Treatment is also more likely to be effective if started early on. He's documented his research in several books, including The End of Alzheimer's and The Ageless Brain. Together, the pair have worked to maintain her progress. She's become a brain health coach and a yoga instructor, and, as Bredesen described her, 'a survivor of cognitive decline, and a remarkable role model for anyone interested in healthy aging.' 'Very very few people are capable of walking 3000 miles, from coast to coast. But to have someone doing it who is 81 years old, and has reversed her cognitive decline after a diagnosis of early Alzheimer's in 2012, is truly historic,' Bredesen told The Independent. 'She is doing something that I could not do, nor could most of the people I know. She is truly an inspiration.' Still, Benjamin's message is simple — offering the hope that cognitive decline can be prevented and reversed. 'That is really the purpose of my journey,' she told The Independent. 'And also to show that you can be 81 years old and walk all this way one step at a time.'